FDA Panel Endorses GSK Vaccine for RSV in Older Adults, a Day After Recommending Pfizer’s Vaccine

A general view of the exterior of the GlaxoSmithKline offices in the Brentford area of London on Oct. 7, 2021. Leon Neal/Getty Images

A committee of outside advisers to the U.S. Food and Drug Administration (FDA) recommended a vaccine from GlaxoSmithKline (GSK) against the respiratory syncytial virus (RSV) for adults over age 60.

The vote from the Vaccines and Related Biological Products Advisory Committee (VRBPAC) for GSK’s Arexvy (RSVPreF3-AS01) vaccine comes a day after the 12 members voted to endorse Pfizer’s vaccine candidate, Abrysvo (RSVPreF), for the same age group.